Patent Number: 6,166,199

Title: N-2 substituted purines

Abstract: This invention presents novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.

Inventors: Cook; Phillip Dan (San Marcos, CA), Ramasamy; Kanda S. (Laguna Hills, CA), Manoharan; Muthiah (Carlsbad, CA)

Assignee: Isis Pharmaceuticals, Inc

International Classification: C07H 19/06 (20060101); C07H 19/04 (20060101); C07H 19/00 (20060101); C07H 23/00 (20060101); C07H 19/10 (20060101); C07H 19/20 (20060101); C07H 19/16 (20060101); C07H 21/00 (20060101); C07J 43/00 (20060101); A61K 38/00 (20060101); C07H 019/00 (); C07H 019/167 ()

Expiration Date: 12/26/2013